Is it better to start with highly intensive MS treatment straight after diagnosis? It’s a question on many a neurologist’s lips and something the DELIVER-MS trial hopes to answer. We spoke to three people involved in the trial to find out what this means.
Dr Omar Abdel-Mannan is a paediatric neurologist trainee at Great Ormond Street Hospital London. He’s researching better ways to measure progression in childhood MS. Lucy Wood, who was diagnosed with MS at the age of 5, spoke to Omar about his research.
Dr Arman Eshaghi from University College London used artificial intelligence to analyse thousands of MRI brain scans in MS. Research Network member Dominic Shadbolt spoke to Arman and told us what it revealed.
Certain DMTs may affect the way your immune system responds to the vaccines. Professor David Baker is a neuroimmunologist from Queen Mary University of London. He’s been keeping track of new results from researchers around the world.
Did you know you can donate your brain and spinal cord to MS research? It’s vital to efforts to find new effective treatments. We asked Ville Pitkaaho, a Research Nurse at the MS Society Tissue Bank some questions about tissue donation so you don’t have to.
We’re partners in Connect Immune Research – a project trying to link the science of autoimmune conditions. Last week, BBC Radio 4’s Woman’s Hour programme spoke about it in a special episode on women’s health.
Max Parmar is Professor of Medical Statistics and Epidemiology at University College London. An expert in clinical trials, he has made countless contributions to medical research. Now he’s turned his attention to MS.
Clinical trials are key to finding treatments for everyone with MS. And although we often focus on the drugs being tested, it’s the people involved who really make these trials happen. In the next instalment of our #BehindTheTrials series, we catch up with three people working to make the MS-STAT2 trial a success as it nears its recruitment goal.